Medifast (NYSE:MED - Get Free Report) is scheduled to be announcing its earnings results after the market closes on Monday, November 4th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Medifast has set its Q3 2024 guidance at -0.700--0.050 EPS.Investors that wish to listen to the company's conference call can do so using this link.
Medifast (NYSE:MED - Get Free Report) last posted its quarterly earnings data on Monday, August 5th. The specialty retailer reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.36 by $0.56. Medifast had a net margin of 3.81% and a return on equity of 25.77%. The business had revenue of $168.56 million during the quarter, compared to analysts' expectations of $160.44 million. During the same quarter in the prior year, the business posted $2.77 earnings per share. On average, analysts expect Medifast to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Medifast Price Performance
MED traded up $0.42 on Monday, hitting $17.84. 120,107 shares of the stock were exchanged, compared to its average volume of 395,771. Medifast has a 12 month low of $17.07 and a 12 month high of $76.42. The business has a 50-day moving average of $18.55 and a two-hundred day moving average of $21.57. The firm has a market capitalization of $195.17 million, a price-to-earnings ratio of 6.68 and a beta of 1.13.
Analyst Upgrades and Downgrades
Separately, DA Davidson reissued an "underperform" rating and set a $17.50 target price on shares of Medifast in a research note on Monday, July 22nd.
Get Our Latest Stock Report on Medifast
About Medifast
(
Get Free Report)
Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.
Further Reading
Before you consider Medifast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medifast wasn't on the list.
While Medifast currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
